On September 28, 2026 Currus Biologics, an Australian biotech developing the BEAT, a proprietary, universal, bispecific antibody platform to unlock CAR T-cell therapy for solid tumours, reported that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its lead programme, CUR-001. The clearance enables Currus to initiate a first-in-human Phase 1 basket trial in patients with mesothelin-positive advanced refractory solid tumours.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CAR T-cell therapies have proved highly effective against blood cancers, yet their impact in solid tumours, which account for around 90% of all cancers, remains limited. In solid tumours, CAR T-cells face a highly immunosuppressive tumour microenvironment (TME) that drives exhaustion and restricts their ability to expand, persist and infiltrate tumour tissue effectively.

CUR-001 combines Currus’ BEAT (Bispecific Engagers of Antigen Presenting Cells and T cells) bispecific antibody, CURB-001 with CURT-001, a FLAG-tagged autologous CAR T-cell therapy targeting mesothelin, a protein expressed at high levels across a range of solid tumours. The BEAT is designed to activate CAR T-cells in lymphoid tissue by engaging both the CAR T-cells and professional antigen-presenting cells, helping to overcome the suppressive effects of the TME. In preclinical solid tumour models, this approach has enhanced CAR T-cell expansion, persistence and tumour infiltration while generating epitope spreading and immunological memory.

Sam Cobb, Chief Executive Officer of Currus Biologics, said: "Receiving IND clearance from the FDA is a major milestone for Currus and an important step in bringing the BEAT into the clinic. CUR-001 is designed to overcome key barriers that have limited the impact of CAR T-cell therapies in solid tumours, an area of significant unmet need. We are excited to progress CUR-001 into Phase 1 and sincerely thank our team, advisers and investors for their support."

Dr Alessandra Cesano, Chair of the Board, Currus Biologics, commented: "Mesothelin has long been considered an attractive target for CAR T-cell therapy in solid tumours, but achieving durable antitumour activity remains a major challenge."

Dr Swami Murugappan, Chief Medical Officer of Currus Biologics, added: "Despite the transformative impact of CAR T-cell therapy in haematological malignancies, achieving durable responses in solid tumours remains a significant challenge. CUR-001 has been designed to address some of the key biological barriers responsible for this difference by combining mesothelin-targeted CAR T-cells with BEAT-mediated immune activation. We look forward to evaluating the safety, pharmacology and early signs of clinical activity of this approach in patients with advanced solid tumours."

(Press release, Currus Biologics, SEP 28, 2026, View Source [SID1234671128])

On September 28, 2026 Mission Bio, the single-cell multiomics leader, reported that Merck & Co. and Incyte will each present new data generated using Mission Bio’s Assay Services and Tapestri Platform at the 16th World Clinical Biomarkers & Companion Diagnostics Summit (World CDx), alongside a third presentation from Mission Bio featuring new clinical data in acute myeloid leukemia. Together, the presentations demonstrate the use of single-cell multiomics from early-stage target validation through clinical mechanism-of-action studies and measurable residual disease assessment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sydney Hart, PhD, Principal Scientist Functional Genomics at Merck & Co. (Merck), will present new functional genomics findings supporting its drug development programs, partnering with Mission Bio’s Assay Services team using the Tapestri Platform. Incyte’s Erin Crowgey, PhD, Director of Translational Medicine, will present new single-cell data on INCA033989, an antibody targeting mutant calreticulin (CALR)-positive cells in myeloproliferative neoplasms disease subtypes. Mission Bio’s Chief Medical Officer, Dr. Zivjena Vucetic, will present new clinical data demonstrating how single-cell measurable residual disease (MRD) profiling improves standard-of-care compared to current methods for acute myeloid leukemia (AML) patients.

The presentations from Merck and Incyte reflect the growing use of Tapestri and Mission Bio’s Assay Services by pharmaceutical companies to answer pipeline-specific questions across drug discovery and clinical development.

MERCK: A SINGLE-CELL PLATFORM FOR LINKING CRISPR-EDITED VARIANTS TO TRANSCRIPTIONAL OUTCOMES
Date: October 8, 2026
Time: 12:20 PM ET
Track: Biomarker Discovery & Translation
Speaker: Sydney Hart, Scientist, Merck & Co.

Merck scientist Sydney Hart, PhD, partnered with Mission Bio’s Assay Services team to build a targeted DNA and RNA single-cell assay on the Tapestri Platform to study how CRISPR-edited genetic variants affect immune cell function in autoimmune and inflammatory disease. Evaluating several single-cell platforms, Merck ultimately selected Mission Bio’s Tapestri Platform for its ability to capture targeted genomic and transcriptional information from the same cell while preserving cell yield, confirming expected disease effects and establishing a mechanistic link for target validation to improve drug development decision-making.

INCYTE: CHARACTERIZING MECHANISM OF ACTION FOR MYELOPROLIFERATIVE NEOPLASMS TARGETED THERAPY (INCA033989) USING SINGLE-CELL MULTIOMICS IN THE CLINIC
Date: October 8, 2026
Time: 11:30 AM ET
Track: Clinical & CDx Development
Speaker: Erin Crowgey, Director of Translational Medicine, Incyte

Incyte’s Erin Crowgey, PhD, will present new single-cell clinical data on their monoclonal antibody, INCA033989, that targets mutant calreticulin (CALR)-positive cells in essential thrombocythemia and myelofibrosis, which are disease subtypes of myeloproliferative neoplasms. These data were generated using a custom Tapestri assay designed by Mission Bio’s Assay Services to measure 46 proteins and 37 genes in the same cell. The single-cell analysis demonstrated depletion of mutant CALR-positive cells and repopulation by wild-type cells with relevant clinical improvements. This illustrates how single-cell multiomics can help characterize the mechanism of action for targeted therapies and track target cell populations and their responses to therapy in the clinic.

MISSION BIO: SINGLE-CELL MRD ASSESSMENT IN AML: ADVANCING BEYOND STANDARD CARE
Date: October 7, 2026
Time: 2:10 PM ET
Track: Clinical & CDx Development
Speaker: Zivjena Vucetic, Chief Medical Officer, Mission Bio

Addressing limitations of standard-of-care AML MRD assays like bulk NGS and flow cytometry due to complex clonal evolution and overlapping immunophenotypes, Dr. Vucetic will present clinical study data showing that single-cell multiomics achieved 93% sensitivity compared to 43% for flow cytometry and 71% for other molecular methods. Additional evidence presented will also support that single-cell MRD profiling provides more accurate stratification of relapse-free survival in AML patient samples.

Single-cell multiomic approaches are redefining how functional genomic and clinical readouts are applied across drug development. In discovery, these approaches link genetic edits to their functional consequences to support target validation. In the clinic, they characterize how a targeted therapy acts on disease-driving cells and track molecular response over time. For MRD monitoring, single-cell data offer evidence to better anticipate relapse. Together, the three presentations illustrate how single-cell multiomics can connect genetic variation to cellular function, characterize treatment response in individual cell populations, and identify residual disease with greater resolution across drug development pipelines.

All talks are open to registered World CDx attendees. Full agenda and registration details are available at View Source

(Press release, Mission Bio, SEP 28, 2026, View Source [SID1234671127])

On September 28, 2026 Tolerance Bio, Inc. ("Tolerance Bio" or the "Company"), a biotechnology company focused on preserving, regenerating and modulating thymic function to address immune diseases and extend healthspan, reported an exclusive license agreement across all indications with Tanabe Pharma Corporation ("Tanabe Pharma") granting Tolerance Bio worldwide development rights and exclusive commercialization rights outside Japan for MT-2990, now TLB-33, a clinical-stage anti-IL-33 monoclonal antibody. Tanabe Pharma retains commercialization rights in Japan.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Tolerance Bio is among the first companies specifically targeting thymic biology as a therapeutic strategy to preserve immune resilience and is uniquely positioned with a clinical-stage, multi-modality pipeline focused on thymic function. This agreement further expands the Company’s clinical-stage pipeline, following the recently announced licensing of NeoImmuneTech’s long-acting interleukin 7 (IL-7), efineptakin alfa. Tolerance is preparing to advance TLB-33 into Phase 2 clinical development to evaluate its potential to preserve thymic function and enhance immune resilience, with additional immune indications also under consideration. The Company also expects to announce the completion of a financing round to support the advancement of TLB-33 and efineptakin alfa through planned clinical trials.

The addition of TLB-33 broadens Tolerance Bio’s pipeline across therapeutic modalities focused on thymus biology, including biologics, mRNA and cell therapies. Together, these programs are designed to preserve, regenerate, and modulate thymic function and collectively position the Company to build the leading therapeutic platform targeting thymic biology.

TLB-33 has been evaluated in over 150 subjects across multiple clinical studies, providing substantial human safety and proof-of-biological principle data that strongly supports further clinical development in new indications such as thymic preservation. Tolerance Bio’s management team brings significant experience identifying, repositioning and advancing clinical-stage assets in new indications, including at Celimmune and Provention Bio.

"This agreement represents another important milestone for Tolerance Bio as we continue to build a clinical-stage pipeline around complementary approaches to thymic biology," said Francisco Leon, MD, PhD, Chief Executive Officer of Tolerance Bio. "TLB-33 is a well-characterized clinical-stage antibody with substantial human safety and pharmacologic data, and its development builds on our team’s experience repositioning clinical-stage assets in high-value new indications," Leon continued. "IL-33 signaling has been implicated in thymic involution in inflammatory settings, and we believe that blocking IL-33 offers an opportunity to preserve thymic function and improve immune resilience. Together with our recently licensed long-acting IL-7 program, TLB-33 gives us complementary approaches to preserving and restoring thymic function."

Under the terms of the agreement, Tanabe Pharma has granted Tolerance Bio exclusive rights to develop and manufacture TLB-33 worldwide across all indications and to commercialize it outside Japan. Tanabe Pharma retains commercialization rights in Japan. The license includes potential development and sales milestone payments of up to approximately $560 million, as well as equity consideration and tiered royalties on net sales.

About TLB-33 (MT-2990) and the thymus

TLB-33/MT-2990 is a clinical-stage human immunoglobulin G1 (IgG1) monoclonal antibody that binds to and neutralizes interleukin-33 (IL-33).

IL-33 is an alarmin released upon cellular stress or tissue injury that drives activation of innate and adaptive immune responses. Dysregulated IL-33 signaling has been implicated in inflammatory pathways believed to contribute to thymic dysfunction and the progressive decline of immune function with age as well as acute thymic involution in certain immune conditions.

TLB-33 has been evaluated in over 150 subjects across five clinical studies. The safety, tolerability, pharmacologic and clinical data generated to date support clinical development in new indications aligned with Tolerance Bio’s strategy.

The thymus plays a central role in T-cell maturation and immune competence, but progressively involutes with age and in the context of acute inflammatory triggers. This decline contributes to increased susceptibility to infections, cancer, autoimmunity and reduced vaccine responsiveness. The Company is advancing TLB-33 to evaluate its potential to preserve thymic output and enhance immune resilience, with additional development planned in certain immune diseases.

(Press release, Tolerance Bio, SEP 28, 2026, View Source [SID1234671126])

On September 28, 2026 Pfizer Inc. (NYSE: PFE) reported it will present data from 45 company-sponsored, investigator-sponsored, and collaborative research abstracts at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress, taking place October 23-27, 2026 in Madrid, Spain. The presentations include 11 oral presentations spanning Pfizer’s established medicines and late-stage pipeline across its disease areas of focus, including breast cancer, genitourinary cancers, and lung cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"At Pfizer Oncology, we’re focused on improving outcomes for people living with cancer. That means continuing to raise the standard of care today while pursuing the breakthroughs that will shape the future of oncology. The data we’re presenting at ESMO (Free ESMO Whitepaper) reflect that focus, strengthening the evidence behind medicines such as PADCEV and TALZENNA, while advancing promising investigational candidates including atirmociclib and tivunatamig. By building on our leadership in breast, genitourinary, and lung cancers, we’re working to bring meaningful progress to patients today and for years to come."

– Jeff Legos, Chief Oncology Officer, Pfizer

Key Highlights of Pfizer’s Presence at ESMO (Free ESMO Whitepaper) 2026

Guiding the Next Wave of Oncology Innovation

Phase 2 randomized results from the FOURLIGHT-1 study of atirmociclib, a highly selective cyclin-dependent kinase (CDK) 4 inhibitor, plus fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (MBC) who had received prior CDK 4/6 inhibitor-based treatment. These results further support atirmociclib as a potential first-in-class cell cycle inhibitor backbone for HR+, HER2- MBC and Pfizer’s development strategy in earlier lines of therapy. A Phase 3 study in frontline MBC is ongoing and an additional Phase 3 study in early breast cancer is planned to evaluate atirmociclib in combination with giredestrant, an investigational oral selective oestrogen receptor degrader under development by Roche. (Presentation #1842O)
Late-breaking overall survival (OS) and progression-free survival (PFS) results from the Phase 3 SigVie-002 study evaluating sigvotatug vedotin (SV), an investigational integrin β6 (IB6)-directed antibody-drug conjugate (ADC), as monotherapy in previously treated non-squamous non-small cell lung cancer (NSCLC). The findings will provide additional insight into previously announced topline results and inform the continued development of SV in earlier treatment settings, including an ongoing Phase 3 trial evaluating SV in combination with pembrolizumab in first-line advanced NSCLC and additional novel combinations under evaluation. (Presentation #LBA68)
Updated Phase 2 data for tivunatamig (PF-08634404, PF’4404), a novel bispecific antibody targeting PD-1 and VEGF, in combination with chemotherapy in first-line PD-L1-expressing NSCLC. Tivunatamig is being developed as a potential best-in-class backbone therapy designed to combine two validated and complementary pathways in a single agent across tumor types, including ongoing pivotal studies in first-line NSCLC, first-line metastatic colorectal cancer, and advanced/recurrent endometrial cancer. Additional Phase 3 combination studies are planned, including with PADCEV (enfortumab vedotin-ejfv) in metastatic urothelial cancer. (Presentation #2660P)
Expanding Evidence Across the Portfolio

Updated exploratory analyses from the Phase 3 EV-302 trial evaluating outcomes with PADCEV plus pembrolizumab in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC), including among older patients, patients with comorbidities, and subgroups defined by disease-related characteristics. The findings further strengthen confidence in the regimen as a first-line foundation of care in la/mUC across clinically relevant populations. (Presentations #4760P and #4761P)
Results from STARBOARD, a non-registrational Phase 3 trial evaluating an investigational triplet combination regimen of BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) with pembrolizumab (KEYTRUDA) in first-line BRAF V600-mutant advanced melanoma. These findings contribute important evidence to an evolving treatment landscape. (Presentation #2071O)
Deepening Understanding of Treatment Outcomes and Patient Experience

Patient-reported outcomes and a safety analysis from the Phase 3 TALAPRO-3 study further supporting TALZENNA (talazoparib) plus XTANDI (enzalutamide) as a potential treatment option for men with homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC; also known as metastatic APMN/S prostate cancer). A supplemental New Drug Application (sNDA) for TALZENNA plus XTANDI in mAPMN/S is currently under Priority Review by the U.S. Food and Drug Administration (FDA). (Presentations #2222RO and #2231P)
An ad-hoc analysis from the Phase 3 EV-303 trial (also known as KEYNOTE-905) and circulating tumor DNA (ctDNA) and health-related quality of life analyses from the Phase 3 EV-304 (KEYNOTE-B15) trial. These analyses provide important biological and patient-centered context to previously reported survival data and further support perioperative PADCEV plus pembrolizumab as a new potential standard of care in muscle-invasive bladder cancer (MIBC). (Presentations #4733O, #4734O and #4738RO)
ESMO Presence Reinforces Pfizer Oncology’s Strategy to Advance Standards of Care and Deliver Next-Generation Breakthroughs

As cancer remains the second-leading cause of death worldwide, Pfizer is focused on generating the evidence needed to bring treatment breakthroughs to as many patients as possible. Our data at ESMO (Free ESMO Whitepaper) reflect that strategy, concentrating innovation in disease areas with the greatest opportunity to impact patients globally. Highlights include emerging data from late-stage investigational programs advancing next-generation treatments, new analyses supporting established medicines as standards of care, and insights that deepen understanding of patient experience to better inform clinical decisions.

Detailed Presentation Information

Information on significant Pfizer and partner-sponsored abstracts, including date and time of presentation, follows in the chart below. A complete list of Pfizer and partner-sponsored abstracts and presentations is available here.

LUNG CANCER

Proffered Paper 1 LBA68

October 25, 2026 10:15–11:45 CET

Phase 3 study of sigvotatug vedotin (SV) vs docetaxel in previously treated non-squamous non-small cell lung cancer (NSCLC) [LBA]

Peters et al

Poster Presentation 2660P

October 26, 2026 12:00–12:45 CET

Phase 2 trial of the PD-1/VEGF bispecific antibody, PF-08634404 (SSGJ-707), plus chemotherapy (chemo) in advanced NSCLC: Updated results [3SBio]

Wu et al

BREAST CANCER

Proffered Paper Session 1842O

October 24, 2026 08:30–10:00 CET

Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK 4/6 inhibitor (CDK 4/6i) in a randomized phase 2 study (FOURLIGHT-1)

Giordano et al

Proffered Paper Session 1766RO

October 24, 2026 10:15–11:45 CET

Health-related quality of life from HER2CLIMB-05: A Phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC

Dieras et al

GENITOURINARY CANCERS: BLADDER AND PROSTATE

Rapid Oral Session 2219RO

October 23, 2026 13:30–15:00 CET

Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metastatic castration-sensitive prostate cancer (mCSPC)

Azad et al

Rapid Oral Session 2222RO

October 23, 2026 13:30–15:00 CET

Patient-reported outcomes (PROs) in men with metastatic castration-sensitive prostate cancer (mCSPC) and homologous recombination repair (HRR) gene alterations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from the Phase 3 TALAPRO-3 study

Azad et al

Proffered Paper Session 4733O

October 23, 2026 13:30–15:00 CET

Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in patients (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: Ad hoc analysis from KEYNOTE-905 [MSD led]

Ullén et al

Proffered Paper Session 4734O

October 23, 2026 13:30–15:00 CET

ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin [MSD led]

Chatzkel et al

Poster Presentation 2296P

October 23, 2026, 15:15-16:00 CET

Safety and efficacy of mevrometostat monotherapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

J. Carles Galceran et al

Poster Presentation 2231P

October 23, 2026 15:15–16:00 CET

Talazoparib (TALA) + enzalutamide (ENZA) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR) gene alterations: Safety analyses from the Phase 3 TALAPRO-3 study

Mateo et al

Poster Presentation 4761P

October 23, 2026 15:15–16:00 CET

Enfortumab vedotin plus pembrolizumab (EV+P) for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Updated exploratory analysis of EV-302 in older patients (pts) and those with comorbidities

Sridhar et al

Poster Presentation 4760P

October 23, 2026 15:15–16:00 CET

Enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Exploratory analyses based on disease-related characteristics from EV-302

Bedke et al

Proffered Paper Session 4738RO

October 24, 2026 10:15–11:45 CET

Health-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) eligible for cisplatin in the phase 3 KEYNOTE-B15 study [MSD led]

Gómez De Liaño et al

MELANOMA

Proffered Paper Session 2071O

October 23, 2026 16:15–17:45 CET

STARBOARD Phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (PBO) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma

Schadendorf et al

Pfizer is continuing its commitment to help non-scientists understand the latest findings with the development of abstract plain language summaries (aPLS) for company-sponsored research being presented at ESMO (Free ESMO Whitepaper), which are written in non-technical language. Those interested in learning more can visit www.Pfizer.com/apls to access the summaries.

Pfizer and Astellas have a clinical collaboration agreement with Merck to evaluate the combination of PADCEV and KEYTRUDA in patients with previously untreated metastatic urothelial cancer and MIBC regardless of cisplatin eligibility. KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada). XTANDI is jointly developed and commercialized by Pfizer and Astellas in the United States.

(Press release, Pfizer, SEP 28, 2026, View Source [SID1234671125])

On September 28, 2026 AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage pharmaceutical company focused on the discovery and development of small molecule therapeutics derived from its boron chemistry platform, reported that the Gates Foundation has awarded an extension of funding to support AN2 Therapeutics’ research activities under its ongoing tuberculosis (TB) research collaboration with GSK focused on the development of boron-based leucyl-tRNA synthetase (LeuRS) inhibitors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TB remains a major global public health challenge. Globally, TB is the world’s leading cause of death from a single infectious agent and among the top 10 causes of death. 1

"We are grateful for the Gates Foundation’s continued support of this important collaboration with GSK to advance boron-based LeuRS inhibitors for the treatment of tuberculosis," said Vince Hernandez, Senior Vice President of Research & Head of Chemistry of AN2 Therapeutics. "The award of additional funding reflects the progress made by the collaboration and the potential of boron chemistry to enable the discovery of differentiated medicines against challenging infectious disease targets. Together with GSK, we remain committed to advancing innovative approaches that may contribute to the development of new treatment options for people affected by tuberculosis around the world."

Hernandez continued, "This collaboration builds upon decades of experience in boron chemistry and the validation of LeuRS as a therapeutic target. We believe the continued support from the Gates Foundation reinforces the importance of pursuing new approaches to help address one of the world’s most pressing infectious diseases."

Dr. Harmony P. Garges, Chief Global Health Officer, GSK, said: "Tuberculosis continues to have a devastating impact on global health, and new treatment options remain urgently needed. We are pleased to continue our collaboration with AN2 Therapeutics and appreciate the ongoing support of the Gates Foundation as we work to advance innovative science that has the potential to contribute to future TB treatment efforts."

LeuRS is a clinically validated target and is the same target underlying epetraborole (in development for M. abscessus lung disease), ganfeborole (which demonstrated proof-of-concept efficacy in a Phase 2 TB study), and tavaborole, an FDA-approved antifungal. AN2’s boron chemistry platform has demonstrated the ability to generate potent inhibitors of LeuRS and other targets that may not be readily addressed using traditional medicinal chemistry approaches.

About Tuberculosis

Tuberculosis is caused by Mycobacterium tuberculosis and remains one of the leading causes of death from an infectious disease worldwide. In 2024, an estimated 10.7 million people fell ill from TB worldwide.2 Despite existing treatments, significant unmet need remains for new therapeutic options that can further improve outcomes and help address the global burden of disease.

(Press release, AN2 Therapeutics, SEP 28, 2026, View Source [SID1234671124])